Clinuvel Pharmaceuticals Ltd
F:UR9A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
F:UR9A
|
AU |
|
D
|
DBS Group Holdings Ltd
SWB:DEVL
|
SG |
Intrinsic Value
The intrinsic value of 
Clinuvel Pharmaceuticals Ltd (UR9A) under the Base Case is 5.04 EUR per share.
Compared with the current market price of 4.56 EUR, the stock appears
Undervalued by 10% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Clinuvel Pharmaceuticals Does
Clinuvel Pharmaceuticals is a specialty drug company that makes treatments for rare skin and light-sensitivity disorders. Its best-known product is SCENESSE, a prescription medicine used to help people with erythropoietic protoporphyria, a condition that can make sunlight exposure painful and difficult to manage. The company also works on other therapies linked to skin protection and pigmentation.
- Headquarters
- Australia AU
- Employees
- 16
- IPO date
- Feb 13, 2001
Earnings Waterfall
Clinuvel Pharmaceuticals Ltd
The intrinsic value for Clinuvel Pharmaceuticals Ltd (UR9A) under the Base Case is 5.04 EUR.
Compared with the current market price of 4.56 EUR, the stock appears Undervalued by 10% .